HC Wainwright Cuts Oncolytics Biotech (NASDAQ:ONCY) Price Target to $5.00

Oncolytics Biotech (NASDAQ:ONCY) had its price objective trimmed by HC Wainwright to $5.00 in a research note published on Wednesday,Benzinga reports. The firm currently has a buy rating on the stock. HC Wainwright also issued estimates for Oncolytics Biotech’s Q4 2026 earnings at ($0.07) EPS, FY2026 earnings at ($0.30) EPS, Q2 2027 earnings at ($0.05) EPS, Q3 2027 earnings at ($0.05) EPS, Q4 2027 earnings at ($0.06) EPS, FY2027 earnings at ($0.21) EPS, FY2028 earnings at ($0.19) EPS, FY2029 earnings at ($0.19) EPS and FY2030 earnings at $0.00 EPS.

ONCY has been the topic of several other research reports. Weiss Ratings upgraded shares of Oncolytics Biotech from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday, July 13th. Wall Street Zen downgraded shares of Oncolytics Biotech from a “hold” rating to a “sell” rating in a research note on Saturday, May 16th. One research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $5.00.

Oncolytics Biotech Trading Up 5.2%

Shares of ONCY opened at $0.84 on Wednesday. Oncolytics Biotech has a 1 year low of $0.73 and a 1 year high of $1.51. The stock has a market cap of $107.50 million, a P/E ratio of -2.48 and a beta of 1.13. The stock’s 50-day moving average price is $0.86 and its two-hundred day moving average price is $0.92.

Oncolytics Biotech (NASDAQ:ONCY) last posted its earnings results on Wednesday, August 12th. The company reported ($0.08) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.05) by ($0.03). As a group, equities analysts forecast that Oncolytics Biotech will post -0.26 EPS for the current year.

Hedge Funds Weigh In On Oncolytics Biotech

Several institutional investors and hedge funds have recently modified their holdings of the business. Renaissance Technologies LLC bought a new stake in Oncolytics Biotech during the 1st quarter worth approximately $608,000. Citadel Advisors LLC bought a new position in Oncolytics Biotech in the third quarter valued at approximately $535,000. Connective Capital Management LLC acquired a new position in shares of Oncolytics Biotech in the fourth quarter valued at approximately $131,000. Susquehanna International Group LLP boosted its holdings in shares of Oncolytics Biotech by 224.6% in the second quarter. Susquehanna International Group LLP now owns 134,129 shares of the company’s stock valued at $127,000 after buying an additional 92,806 shares during the period. Finally, XTX Topco Ltd bought a new stake in shares of Oncolytics Biotech during the fourth quarter worth $69,000. 6.82% of the stock is currently owned by institutional investors and hedge funds.

Trending Headlines about Oncolytics Biotech

Here are the key news stories impacting Oncolytics Biotech this week:

• Positive Sentiment: The company gained FDA alignment on its REO 033 clinical trial, a favorable development that may reduce regulatory uncertainty and support progress in its oncology pipeline. Oncolytics Biotech gains FDA alignment on REO 033 trial
• Positive Sentiment: HC Wainwright maintained a Buy rating and a $5.00 price target for Oncolytics Biotech. That target remains substantially above the stock’s recent trading level, signaling significant potential upside if the company’s clinical programs advance successfully. HC Wainwright Lowers Oncolytics Biotech Price Target to $5.00
• Neutral Sentiment: The FDA alignment is strategically important, but Oncolytics remains a development-stage biotechnology company whose valuation depends heavily on future clinical data, regulatory milestones and funding availability.
• Negative Sentiment: HC Wainwright reduced its EPS forecasts across multiple periods: FY2026 to a loss of $0.30 per share from $0.28, FY2027 to a loss of $0.21 from $0.15, FY2028 to a loss of $0.19 from $0.14, and FY2029 to a loss of $0.19 from $0.12. Quarterly 2026–27 loss estimates were also lowered, while FY2030 was reduced to breakeven from expected earnings of $0.14. The revisions indicate analysts expect a slower path to profitability, creating a counterweight to the positive trial news. HC Wainwright Lowers Oncolytics Biotech Price Target to $5.00

Oncolytics Biotech Company Profile

Oncolytics Biotech Inc (NASDAQ: ONCY) is a clinical-stage biotechnology company focused on the development of novel oncolytic viral therapies for the treatment of cancer. The company’s lead investigational agent, pelareorep (Reolysin), is a proprietary formulation of reovirus engineered to selectively infect and destroy tumor cells while stimulating a systemic antitumor immune response. Oncolytics leverages the natural biology of the virus to enhance the activity of standard?of?care treatments and immune checkpoint inhibitors.

Pelareorep has progressed into multiple advanced clinical trials, with combination studies conducted in metastatic breast cancer, non?small cell lung cancer and head and neck cancers.